CareDx to Acquire Naveris to Expand Into Cancer MRD Testing
By Daniella Parra CareDx (Nasdaq: CDNA) said it signed a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company, for up to $260 million and will close in the third quarter. Naveris makes NavDx, a blood-based test that...